The Efficacy and Safety of Vinpocetine in the Treatment of Patients with Chronic Vascular or Degenerative Senile Cerebral Dysfunction
Marino Peruzza, M.D., Maurizio Dejacobis, M.D.
Uníversity of Pavia.
G.B. Glustinian Regional Hospital. Venice, Italy
Advances in therapy 1986; 4:201-4
Abstract
In a double-blind clinical trial, 22 elderly patients with cerebrovascular and central nervous system degenerative disorders were treated with
vinpocetine, a synthetic ethyl ester of apovincamine.
They received 10 mg vinpocetine t.i.d. for 30 days, then 5 mg t.i.d. for 60 days. Matching placebo tablets were given to another 20 elderly patients for the 90-day trial period.
Patients
on vinpocetine scored consistently better in all evaluations of the effectiveness of treatment including measurements on the Clinical Global Impressions
and Sandoz Clinical Assessment-Geriatric Seales and the Mini-Mental Status Questionnaire.
No
serious side effects were related to the treatment drug.